CommercialCoverageMedium impact
Predictive Testing for Pancreatic Cancer 2.02.39
Excellus BlueCross BlueShield·Gastroenterology, Oncology, General Surgery +1 more·Lab Tests (pathology)
Effective date
Dec 18, 2025
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield now considers all predictive molecular testing for pancreatic cancer risk assessment as investigational and non-covered, including PancreaGen, BT-Reveal, PancreaSeq, and PanCystPro tests. This policy establishes that these genetic tests will not be reimbursed as they are deemed experimental.
Action Required
By December 18, 2025: Billing team must update system to flag pancreatic cancer predictive tests (PancreaGen, BT-Reveal, PancreaSeq, PanCystPro) as non-covered investigational services for Excellus BlueCross BlueShield. Inform providers that these tests require patient financial responsibility discussions and ABNs. Claims for these services will be denied as investigational.